Cargando…
MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine
BACKGROUND: Methyl-CpG binding domain protein 1 (MBD1), which couples DNA methylation to transcriptional repression, has been implicated in transcriptional regulation, heterochromatin formation, genomic stability, cell cycle progression and development. It has also been proven that MBD1 is involved...
Autores principales: | Wensheng, Liu, Bo, Zhang, Qiangsheng, Hu, Wenyan, Xu, Shunrong, Ji, Jin, Xu, Quanxing, Ni, Xianjun, Yu, Xiaowu, Xu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734348/ https://www.ncbi.nlm.nih.gov/pubmed/31516389 http://dx.doi.org/10.1186/s12935-019-0948-1 |
Ejemplares similares
-
Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma
por: Sun, Qiqing, et al.
Publicado: (2019) -
FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
por: Hu, Qiangsheng, et al.
Publicado: (2017) -
PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis
por: Qin, Yi, et al.
Publicado: (2019) -
Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab‐paclitaxel in pancreatic cancer
por: Zhang, Zheng, et al.
Publicado: (2021) -
ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells
por: Chen, Haidi, et al.
Publicado: (2021)